Fig. 3
From: Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy
The anti-tumor ability of the intranasal circRNA vaccine is tumor antigen and cDC1 dependent. a Timeline of the experiment designed to evaluate the anti-tumor ability of the intranasal RNA vaccine. Wild-type (WT) mice were challenged with B16-OVA-luciferase cells and then left untreated (NT), treated with RFP-coding or SIINFEKL (OVA peptide)-RFP-coding RNA. Tumor growth was monitored through bioluminescence imaging. b Statistical analysis of the average bioluminescence radiance with different treatments. Data were analyzed with two-way ANOVA with Tukey’s multiple comparisons test. n = 3 for NT group. n = 4 for other groups. c Survival curve of the WT mice with different treatments. Data were analyzed via Kaplan-Meier analysis. d Timeline of the experiment designed to evaluate the anti-tumor ability of the intranasal RNA vaccine in Batf3−/− mice. e Survival curve of the Batf3−/− mice with different treatments. Data were analyzed via Kaplan-Meier analysis. n = 4 for each group. f Timeline of the experiment designed to evaluate the antigen-specific T cell induction after circRNA vaccination. WT or Batf3−/− mice were intranasally immunized with SIINFEKL-RFP-coding circRNA followed by antigen-specific T cell evaluation at lung and spleen tissues (n = 3, repeated for three times). g Statistical analysis of the ratio of antigen-specific T cells. Data were analyzed with two-way ANOVA with Tukey’s multiple comparisons test. All data are represented as mean ± SEM
